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Abstract: Prostate cancer (PCa) is one of the most common cancers in older men and is associated with
high mortality. Despite advances in screening for early detection of PCa, a large proportion of patients
continue to be diagnosed with metastatic disease, with ~20% of men showing a high tumor grade
and stage. Medicinal plant extracts have a great potential to prevent/treat PCa, as well as to reduce its
incidence/prevalence and improve survival rates. One of the most promising extracts is curcumin,
which is a major, nontoxic, bioactive compound of Curcuma longa. Curcumin has strong antitumor
activity in vitro. However, its potential beneficial in vivo affects are limited by its low intestinal
absorption and rapid metabolism. In this study, curcumin was impregnated into a biodegradable
poly(lactic-co-glycolic) acid (PLGA) support and characterized by FTIR and DSC, and its release
by UV spectrophotometry. PLGA-curcumin was tested in different subcutaneous PCa xenograft
models (PC3, 22rv1, and DU145 PCa cell-lines), and its effects evaluated by tumor progression an
immuno-histochemical analysis (Trichromic, Ki67 and TUNEL stainings), were compared with those
of a commercial curcumin preparation. Our results indicate that curcumin-impregnated PLGA is
significantly more active (~2-fold increase) with respect to oral curcumin, which supports its use for
subcutaneous administration.
Keywords: curcumin; PLGA polymer; supercritical carbon dioxide impregnation; curcumin release;
prostate cancer; mice xenograft model
1. Introduction
Prostate cancer (PCa) is the second largest cancer histotype and the fifth leading cause of
cancer-associated deaths in older men worldwide [1,2]. There is evidence to suggest a close relationship
between oxidative stress, inflammation, and risk of progressive PCa [3,4]. Oxidative stress, which
is characterized by an imbalance between the production of reactive oxygen species (ROS) and the
capacity of biological systems to counteract the effects of reactive free radicals or repair oxidative
damage, plays a key role in PCa progression and its response to therapy [5,6]. Whereas low levels of
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intracellular ROS are critical for proper cellular signaling and homeostatic redox balance, high levels
are deleterious and can lead to significant reductions in antioxidant defense mechanisms, which results
in DNA, protein, and lipid damage [5–7]. Oxidative stress contributes to the initiation and progression
of PCa by modulating transcription factors, cell cycle regulators, and DNA [5,8,9]. Against this
background, several antioxidant-related phytochemicals have been tested for the prevention/treatment
of PCa by ameliorating oxidative stress [10–13], and some have the added advantage of low toxicity [14].
Of the different families of compounds naturally present in plants, the polyphenols have shown the
greatest activity against PCa. Some examples are silibinin, luteolin, ellagic acid, epigallocatechin
gallate, and other catechins, or trans-resveratrol [15], which is widely found in food sources such as
grapes, pomegranates, and green tea. Among these, the most promising compound tested for targeting
PCa is curcumin.
Curcumin has a long history of use as a food additive and traditional medicine in many Asian
cultures. It has a broad range of biological activities, including anti-inflammatory, anti-oxidative,
anti-metastatic, and multi-drug resistance reversing properties [16–20]. Curcumin is the major yellow
pigment of turmeric (Curcuma longa), which is a spice found in curry powder. It functions by blocking
cell signaling and inhibiting cell division through specific types of enzymes and growth factors that are
directly involved in cancer development [21]. Pre-clinical studies have demonstrated the anti-cancer
potential of curcumin via its effects on androgen receptor (AR) signaling and downstream targets (e.g.,
VEGF, PTEN, and NF-kB) [22–25]. Specifically, curcumin down-regulates AR expression [22], limits
AR binding to the androgen response element of the prostate-specific antigen (PSA) gene, and reduces
the expression of PSA in human prostatic LNCaP adenocarcinoma cells [26]. The United States Food
and Drug Administration (FDA) has classified curcumin as being generally recognized as safe, and it
is used as a supplement in several countries [27]. Moreover, phase I clinical studies show that oral
curcumin is non-toxic to humans at doses up to 8000 mg/day for three months [28]. Nevertheless, there
are several limitations to the use of curcumin as a therapeutic agent, including its poor bioavailability
(low absorption, limited tissue distribution, and rapid metabolism) [29,30].
When ingested, curcumin is absorbed by passive diffusion through the plasma membrane of
intestinal endothelial cells. It then undergoes numerous bio-transformations by the local action of
bacteria and enzymes, and is recognized as a xenobiotic by specific transmembrane proteins belonging
to the ABC-transporter family (e.g., P-gp, MRPs, and BCRP), which is responsible for translocating
curcumin from the interior of the enterocyte to the lumen where it is eliminated by fecal excretion [31].
Accordingly, curcumin has low absorption and, thus, poor bioavailability.
The three most common strategies for overcoming the poor bioavailability of curcumin
are: (1) concomitant consumption of curcumin with other natural compounds such as
piperine [32], which inhibits the activity of ABC transporters and prevents the return of
curcumin to the intestinal light [33], (2) chemical modification of the curcumin molecule to
obtain analogues in the form of hydrazinocurcumin [34], diphenyl difluoroketone [35], or PAC
(3,5-bis(4-hydroxy-3-methoxybenzylidene)-N-methyl-4-piperidone) [36], which are more soluble
and bioavailable, or (3) encapsulation methods, for the design of drug delivery systems, such as
nanoparticles or solid molecules of small dimensions (1 to 600 nm) [37], micelles formed by monolayers
of phospholipids [38], liposomes with several layers of amphipathic lipids [39], or niosomes formed
by surfactants or non-ionic surfactants that form vesicles without the presence of phospholipids and
cholesterol [40].
Of all these options, the most attractive is encapsulation with biocompatible polymers. In this
respect, poly(lactic-co-glycolic) acid (PLGA) is one of the most common biodegradable matrices used to
encapsulate many compounds with biological activity, including the anti-tumor agents doxorubicin [41]
and paclitaxel [42], and is approved by the FDA for contact with biological fluids, with potential
applications in wound closure and surgical sutures, delivery carriers, tissue engineering scaffolds, or
various types of implants [43,44].
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In the case of curcumin, PLGA has been used to produce particles and nanoparticles using
diverse techniques such as nanoprecipitation [45], coaxial electrospray processes [46], and liquid-driven
co-flow focusing [47], or by methods that allow the particles to have super-paramagnetism [48]. In the
present work, we used the supercritical carbon dioxide (scCO2) approach to fabricate a PLGA polymer
impregnated with curcumin, which has been previously shown to result in the absence of residues
and to have a high impregnation efficiency [49]. We characterized the in vitro release of curcumin and
designed a protocol of periodic administration of this complex in three PCa xenograft models using
PC3, DU145, and 22rv1 prostate carcinoma cell lines. We also compared this curcumin-impregnated
PLGA scaffold with an improved commercial preparation (MicroActive© curcumin), which is designed
to overcome the bioavailability difficulties.
2. Materials and Methods
2.1. Materials
For the production of the PLGA support, glycolide (G) and D,L-lactide (L) with a purity higher
than 99.5% were purchased from Purac Biochem BV (Gorkum, The Netherlands). Curcumin used
for impregnation had a purity higher than 98% (Wellgreen Technology Co. Ltd., Xi’an, China).
MicroActive® curcumin (25%) was supplied by Comercial Química Massó S.A. (Barcelona, Spain).
Other reagents used were: CO2 (Carburos Metálicos, S.A., Madrid, Spain) with a purity of 99.5%,
and stannous octoate (Sigma-Aldrich, Madrid, Spain), and acetone–analytical grade (VWR, S.A.,
Madrid, Spain).
2.2. Impregnation of PLGA Using a Supercritical Carbon Dioxide
Polymerization of PLGA in a molar ratio (L:G) 80:20 and the supercritical impregnation of polymer
with curcumin was carried out as described [49], but with the following slight modifications: 1000 mg
of solid PLGA was mixed with a solution of acetone containing 170 mg of curcumin and placed in a
high-pressure vessel where CO2 was compressed to 150 bar at a temperature of 45 ◦C. The contact time
for this impregnation was 8 h to ensure total solubilization.
2.3. Impregnated Polymer Characterization
2.3.1. Fourier-Transform Infrared Spectroscopy
Fourier-transform infrared (FTIR) spectra of the impregnated polymer were obtained with a
Varian model 640-IR spectrometer (Varian Inc., Palo Alto, CA, USA) in the range from 4000 to 400 cm−1,
with a resolution of 4.0 cm−1 and 64× scanning, using Varian Resolution software (Varian Inc.).
2.3.2. Ultraviolet-Visible Spectrophotometry
Ultraviolet-visible spectrophotometry (UV-Vis) was used to determine the yield obtained in the
PLGA impregnation step, as well as to establish the in vitro release of curcumin. In the first case, the
high solubility of curcumin in acetone was used to calculate the yield. An eight-point calibration curve
dissolving pure curcumin (0.025–0.250 mg/mL) in acetone was carried out (y = 7.664x − 0.0857, where
y means concentration of curcumin in mg/ml and x absorbance reading, r2 = 0.999). For the in vitro
release experiment, 30 mg of polymer impregnated with curcumin was suspended in 0.1 M phosphate
buffered saline (PBS) (pH 7.4), in a 100-mL flask hermetically closed and protected from light, stirred at
100 rpm, and incubated in a shaking water bath at 37 ◦C. Samples of 5 mL were periodically removed
from the flask to measure the quantity of curcumin released. The measurements were carried out using
a Shimadzu UV-1603 dual beam UV spectrophotometer (Kyoto, Japan) at an absorption maximum of
421 nm using UVPC Personal Spectroscopy Software, version 3.6 (Shimadzu, Kyoto, Japan).
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2.3.3. Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry (DSC) analysis was determined using the DSC Q100 platform
(TA Instruments, Newcastle, DE, USA). Samples of 3–10 mg were prepared in aluminum capsules.
The samples were heated to 280 ◦C with a ramp of 10 ◦C/min, which is followed by cooling until
−50 ◦C at the same rate and, lastly, heated again to 280 ◦C with the same ramp.
2.4. Xenograft Model
Six-week-old male CD1 nude mice (Charles River, Milan, Italy) were maintained under the
guidelines established by our Institution (University of L’Aquila, Medical School and Science and
Technology School Board Regulations, complying with the Italian government regulation n.116, 27
January, 1992 for the use of laboratory animals). All mice received a subcutaneous flank injection of
1 × 106 PC3, DU145 or 22v1 cells. Tumor growth was monitored by bi-weekly measurement of the
tumor diameter using a Vernier caliper (length × width). Tumor weight (TW) was calculated according
to the formula: TW (mg) = tumor volume (mm3) = d2 ×D/2, where d and D are the shortest and longest
diameters, respectively. The effects of the treatments were examined as previously described [50].
2.5. Treatments for In Vivo Experiments
Before starting treatments, animals were randomized into three groups as follows: Group 1:
mice (n = 10) receiving oral administration of 100 µL PBS (control). Group 2: mice (n = 10) receiving
oral administration of 100 mg/kg MicroActive® containing 25% curcumin (Maypro Industries LLC,
Westchester, NY, USA) dissolved in methyl cellulose 0.5% five days weekly for five weeks. Group 3:
mice (n = 10) receiving subcutaneous administration of PLGA-impregnated curcumin (800 mg/kg)
inserted, as a powder, inside a subcutaneous dorsal pocket at day 1, 9, 18, 27, and 34. A scheme of
the protocol followed is shown in Figure 1. Mice were randomized when tumors reached volumes of
0.8–1.3 cm3. The treatment performed on day 34 (one day before euthanasia) was done to maintain
the selective pressure of the impregnated products. The injections of impregnated curcumin were
performed distantly from the tumor cell inoculation sites. Accordingly, with cells injected placed in the
animals’ flanks, the inoculations of the drug were carried out between the scapulae.
Nutrients 2019, 11, x FOR PEER REVIEW 4 of 15 
 
Differential scanning calorimetry (DSC) analysis was determined using the DSC Q100 platform 
(TA Instruments, Newcastle, DE, USA). Samples of 3–10 mg were prepared in aluminum capsules. 
The samples were heated to 280 °C with a ramp of 10 °C/min, which is followed by cooling until −50 
°C at the sa e rate and, lastly, heated again to 280 °C with the same ramp. 
2.4. Xenograft Model  
Six-week-old male CD1 nude mice (Charles River, Milan, Italy) were maintained under the 
guidelines established by our Institution (University of L’Aquila, Medical School and Science and 
Technology School Board Regulations, complying with the Italian government regulation n.116, 27 
January, 1992 for the use of laboratory animals). All mice received a subcutaneous flank injection of 
1×106 PC3, DU145 or 22v1 cells. Tumor growth was monitored by bi-weekly measurement of the 
tumor diameter using a Vernier caliper (length × width). Tumor weight (TW) was calculated 
according to the formula: TW (mg) = tumor volume (mm3) = d2 × D/2, where d and D are the shortest 
and longest diameters, respectively. The effects of the treatments were examined as previously 
described [50]. 
2.5. Treatments for In Vivo Experiments 
Before starting treatments, animals were randomized into three groups as follows: Group 1: 
mice (n = 10) receiving oral administration of 100 µL PBS (control). Group 2: mice (n = 10) receiving 
oral administration of 100 mg/kg MicroActive® containing 25% curcumin (Maypro Industries LLC, 
Westchester, NY, USA) dissolved in methyl cellulose 0.5% five days weekly for five weeks. Group 3: 
mice (n = 10) receiving subcutaneous administration of PLGA-impregnated curcumin (800 mg/kg) 
inserted, as a powder, inside a subcutaneous dorsal pocket at day 1, 9, 18, 27, and 34. A scheme of the 
protocol followed is shown in Figure 1. Mice were randomized when tumors reached volumes of 
0.8–1.3 cm3. The treatment performed on day 34 (one day before euthanasia) was done to maintain 
the selective pressure of the impregnated products. The injections of impregnated curcumin were 
performed distantly from the tumor cell inoculation sites. Accordingly, with cells injected placed in 
the animals’ flanks, the inoculations of the drug were carried out between the scapulae. 
 
Figure 1. Protocol for the drug application to xenografted mice. MicroActive® curcumin by oral 
administration (blue color), and impregnated curcumin by subcutaneous administration (grey color). 
Mice were randomized when tumors reached volumes of 0.8–1.3 cm3. At the end of the experiment 
(35 days after the start of treatments), animals were sacrificed by CO2 inhalation and tumors were 
removed surgically for analyses. 
2.6. Evaluation of Treatment Response In Vivo 
Figure 1. Protocol for the drug application to xenografted mice. MicroActive® curcumin by oral
administration (b ue color), and im regnated curcumin by subcutaneous administration (grey c lor).
Mice we e ra domized when tumors reach volumes of 0.8–1.3 cm3. At the end of the experiment (35
days after the start of treatmen s), animals were sacrificed by CO2 inhalation and tumors w re removed
surgically fo analyses.
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2.6. Evaluation of Treatment Response In Vivo
The following parameters were used to quantify the antitumor effects upon different treatments,
as previously described [50]. (1) The tumor volume measured during and at the end of experiments.
(2) The tumor weight measured at the end of experiment. (3) The tumor progression (TP or doubling
time), defined as an increase of greater than 100% of tumor volume with respect to the baseline, and (4)
time-to-progression (TTP), defined as the time for tumor progression. Taken together, these parameters
provided the data on the percentage of tumors in progression to generate Kaplan-Meier curves.
2.7. Histopathology and Immunohistochemical Analyses
Indirect immunoperoxidase staining was performed on 4-µm-thick paraffin-embedded tissue
sections. The Ki67 labeling index was determined by counting 500 cells at 100× magnification and
determining the percentage of cells staining positively for Ki67. Apoptosis was measured as the
percentage of TUNEL-positive cells measured in five random fields (400×) using the TACS®Blue
Label kit (R&D Systems, Inc., Minneapolis, MN, USA). A consensus judgment was adopted [51] for
immunohistochemical scoring of tumors based on the strength of positivity: negative (score 0), weak
(score 1), moderate (score 2), or strong (score 3) staining. In each category, the percentage of positive
cells was assessed by scoring at least 1000 cells in the area with the highest density of antigen-positive
cells. The percentage of cells was graded as follows: 0 = absence of cells, 1 = <10% positive cells,
2 = positive cells in a range of 10–50%, and 3 = >50% positive cells. Overall expression was defined by
the staining index (SI) and ranged between 0 and 9, with an SI≤4 indicating a low expression. Martius
yellow, brilliant crystal scarlet, and soluble blue (trichrome) staining were used to stain erythrocytes,
and, consequently, the presence of micro-thrombi, bleeding zones, and fibrous stroma.
2.8. Statistical Analysis
Continuous variables were summarized as mean and standard deviation (SD) or 95% confidence
intervals (CIs). Statistical comparisons between controls and treated groups were performed using
analysis of variance or by the Student’s t test for unpaired data (for two comparisons). Dichotomous
variables were summarized by absolute and/or relative frequencies. For dichotomous variables,
statistical comparisons between control and treated groups were established by carrying out Fisher’s
exact test. For multiple comparisons, the level of significance was corrected by multiplying the P-value
by the number of comparisons performed (n), according to the Bonferroni correction. Overall survival
was analyzed with Kaplan-Meier curves and the Gehan’s generalized Wilcoxon test. When more than
two survival curves were compared, the Log rank test for the trend was used. This tests the probability
that there is a trend in survival scores across the groups. All tests were two-sided and were determined
by Monte Carlo significance testing. P-values of at least <0.05 were considered statistically significant.
In the figures in which statistical analysis was performed, the significance is indicated by an asterisk.
The SPSS (IBM Corp., Armonk, NY, USA) version 10.0 and StatDirect (version. 2.3.3., StatDirect Ltd.,
Altrincham, Manchester, UK) were used for statistical analyses and graphic presentations.
3. Results
3.1. Characterization of PLGA Impregnated with Curcumin in scCO2
The PLGA sample impregnated with curcumin in scCO2 is fabricated as described [49]. It was
characterized using three different techniques. FTIR spectra showing different peaks corresponding to
the PLGA-curcumin structure are represented in Figure 2a. The appearance of the most characteristic
absorbance band of PLGA corresponding to the carbonyl group (1760 cm−1), which increased after
impregnation due to the contribution of the C=O group of curcumin. This demonstrated that the
process had taken place correctly.
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Figure 2. Characterization of the poly(lactic-co-glycolic) acid (PLGA) polymer alone and impregnated
with curcumin in scCO2 by (a) FTIR and (b) DSC techniques.
Curcumin-loaded PLGA samples were also characterized by DSC to determine the glass transition
temperature (Tg), which is a useful measure to establish the purity of the resulting product and the
level of residual contamination with the solvent used during the process. As shown in Figure 2b, the
Tg of PLGA impregnated with curcumin was 51.02 ◦C.
Results of the UV-Vis spectrophotometry analysis against the calibration curve in acetone showed
that, of the 170 mg of curcumin used for impregnation, 159.4 mg was actually impregnated, which
resulted in an impregnation yield of 93.8%.
3.2. Curcumin In Vitro Release
The amount of released curcumin was determined by UV-Vis spectra at 421 nm. A calibration
curve in PBS was carried out to determine the release sample profile (Figure 3).
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Figure 3. Curcumin release from impregnated PLGA with curcumin in scCO2 suspended in PBS at
37 ◦C for 10 days. Highlighted are the “burst” (step 1), “internal diffusion” (step 2), and “polymer
degradation” (step 3) phases. See discussion for more details.
According to the results shown in Figure 3, eight days were necessary for the release of more than
90% of the impregnat d drug. After 10 days, almost all curcumin was r le sed into the PBS s luti n.
T e previously determined content (159.4 mg of curcumin per 1000 mg of impregnated PLGA) and the
resul s from the in itro release analysis wer used to desi n the ani al model experiment. During the
five weeks of t experiment, Group 2 (MicroActive® curcumin) mic were treated five days weekly
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at the established concentration (100 mg/kg), as shown in Figure 1, until the day before euthanasia
(day 34). This involved treating each mouse for 26 days with an equivalent amount of curcumin of
650 mg/kg (2600 mg/kg of MicroActive® preparation containing 25% curcumin). Group 3 (impregnated
curcumin) mice were treated five times over the five-week period, with a cadence of eight to nine
days, which is the frequency established by the release trials. This involved treating the mice with a
slightly lower amount of curcumin equivalent (636 mg/kg), since the 800 mg/kg dose on each occasion
contained a lower proportion of curcumin (4000 mg/kg of PLGA impregnated with 15.9% of curcumin).
3.3. Antitumor Effect of Curcumin Preparations in PC3, DU145, and 22rv1 Subcutaneous Xenografts
When compared with the control (PBS) group, both curcumin groups showed antitumor effects
when administered in nude mice with PC3, DU145, and 22rv1 subcutaneous xenografts. In addition,
both curcumin groups showed a significant decrease in tumor size, with the curcumin-impregnated
PLGA group showing a significantly higher anti-tumor effectiveness when compared with the
commercial MicroActive® curcumin group. Figure 4 shows the changes in tumor weight by treatments,
with a reduction of 29% in tumor weight in the MicroActive® curcumin group and 71% in the
curcumin-impregnated PLGA group.
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Figure 4. Aspect and weight of PC3 tumors (shown as an example for the analyses carried out for the
three xenografts), evaluated at the end of the treatment period, and the statistical analysis by groups.
* Statistically significant differences with the control group. # Statistically significant differences with a
MicroActive® group.
To reduce the probability of bias due to differences in tumor engraftment, we analyzed tumor
progression using the TTP parameter, efined as th time (days) necessary to double the volume f r
each tum r, and comparing the differences in progression over tim by the Kaplan-M ier analysis.
As shown in Figure 5a, administration of curcumin-impregnated PLGA signific tly r duced the
progression of the PC3 tumors, with a Hazard ratio (HR) of 4.51 versus the control (CI95% 1.46 to 13.04),
whereas the ral MicroActive® curcumin had an HR value f 2.65 (CI95% 0.80 to 8.78). According t
the performed Logrank test, a hypothesis test sing a Kaplan-Meier estimator to compare the survival
distributions of two samples, demonstrat s that the survival rates (percent ge of tumor progression)
were statistically different in the considered comparisons (Figure 6), which the graphical insp ction
also demonstrat s. However, the achieve HR best estimation showed, for some comparisons, a 95%
CI including the unit. This c uld be due likely to the reduced statistical power (i.e., reduced sampling
size). Ad inistration of MicroActive or PLGA-impregnate curcumin preparations showed no side
effects as indicated by the variations of body weight in treated animals versus controls (Table 1), while
taking into account the contribution of tumors grown in animals.
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Table 1. Body weight comparison of mice, expressed in grams ± standard deviation.
Cell Line Control * MicroActive Curcumin * Impregnated Curcumin *
PC3 25.5 ± 1.2 24.7 ± 1.8 24.0 ± 1.5
DU145 25.2 ± 1.4 24.8 ± 1.3 24.8 ± 1.3
22rv1 23.7 ± 1.5 21.9 ± 1.3 21.9 ± 1.3
* consider the contribution of tumors to the body weight.
3.4. Histopathology and Immunohistochemical Analyses
Histopathological and immunohistochemical analyses were used to confirm the greater
effectiveness of curcumin-impregnated PLGA (Figure 6). Trichrome staining of tumor tissues from
control and curcumin-treated animals showed that the deposition of collagen was higher in both
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curcumin-treated groups than in control animals (ranging from 20% to 50% of the slide area), with
significantly stronger staining in the curcumin-impregnated PLGA group than in the oral curcumin
preparation group (Figure 6a). This was consistent for all three cell-xenograft types. The increase
in fibrosis was accompanied with a decrease in monocyte infiltration, which suggests reduced
inflammation. Ki67 staining of tumor sections showed that both curcumin-treated groups had
significantly less Ki67-positive cells than the control group (Figure 6b), with the curcumin-impregnated
PLGA group showing significantly fewer Ki67-positive cells than the oral curcumin group for two
of the three cell lines tested. Lastly, the percentage of TUNEL-positive cells (apoptotic, dead cells)
was significantly greater in both curcumin-treated groups than in the control group, with significant
differences between the curcumin-impregnated PLGA and the oral curcumin group (Figure 6c).
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Figure 6. istopath logical/immun histo hemical analyses using three different staining techniques
for tu r ro th after PC3 cells subcutaneously injection in male nu/nu mice (xenograft model): (a)
Trichrome staining, (b) Ki67 staining, (c) TUNEL staining, and statistical analysis for the three models
of PCa xenografts. * Statistically significant differences with the control group. # Statistically significant
differences with a MicroActive® group. Magnifications are indicated in the single panels as size bars.
4. Discussion
4.1. Characterization of PLGA Impregnated with Curcumin in scCO2
Supercritical technology, specifically the use of scCO2 as a solvent, is a suitable medium for
pharmaceutical applications due to its excellent properties [52]. This solvent also acts on the polymer
matrix, allowing a phenomenon termed plasticization, which decreases the Tg of a polymer. This allows
a better interaction between the pharmaceutical compound and the polymer [53]. This technology was
applied in the present study for the copolymerization between lactide and glycolide (PLGA), which
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allows the fabrication of scaffolds with high porosity [54] and improves the drug loading capacity by
providing more free space [49].
PLGA, which is FDA-approved, presents a wide variety of properties that make it a superb
candidate for biomedical applications, such as the manufacture of tissue engineering scaffolds
and delivery systems for different bioabsorbable medical implants [43,44]. The Tg reached by the
impregnated polymer (51.02 ◦C) was high and very similar to that observed for the pure polymer
(51.9 ◦C) [49], which indicates that acetone was completely removed from the polymeric matrix. This
is an important feature for formulations to be used for prevention and treatment of cancer without
any additional purification steps [55]. The impregnation yield was also high (93.8%), and superior
to previous work using the same technique [49]. It is among the highest values ever achieved with
PLGA used to encapsulate curcumin. This is above the 70% achieved using liquid-driven co-flow
focusing (LDCF) [47], in the range of 89%–94% obtained by the single emulsion-solvent evaporation
method [56]. This is close to the highest efficiency achieved so far, with 97.5% reported by Anand and
colleagues [57], even though these authors obtained a very low percentage of drug loading (0.4%). This
latter factor is also key when considering PLGA impregnation, since the higher the percentage, the
lower the dose of the final product needed to administer the desired amount of the drug. In this sense,
the results obtained in this work (15.9% drug loading) are well above the usual 5–10% [45,47], and just
below the 30% reached using the electrospray coaxial technique [46].
4.2. Curcumin In Vitro Release
The mechanism for the controlled release of drugs from biocompatible polymers consists of
three steps [7]: (1) solubilization of the drug located on the surface of the particles, which is the
most accessible (burst stage), (2) diffusion of the drug through the pores (internal diffusion), and (3)
solubilization of the entrapped drug when the polymer network is hydrolyzed (polymer degradation).
Taking this drug delivery scheme as a reference, and in view of the results shown in Figure 3, the burst
stage in our case was much less intense than in other PLGA-curcumin applications [45,47,56], likely
because of the previously mentioned plasticizing effect, since there would be a better integration of
curcumin with the polymer. The first stage over the first few hours is similar to the linear evolution that
would be expected for the long-term release, whereas, in other systems, it is much more accentuated.
For example, while in our study there is a release of ~20% in the first 24 h, the same percentage is
reached in other studies within the first hour [56], which reaches 40% in the first 4 hours [45] or in
the first day [47]. It seems that the effect of scCO2 for impregnation of curcumin allows a better
homogeneous distribution of curcumin within the polymer matrix, which leaves only a small quantity
accessible on the outside. This behavior is more characteristic of the release of a hydrophobic substance
(such as curcumin) impregnated in PLGA, whereas the release of curcumin impregnated in PLGA by
other techniques [45,47,56], is more similar to the behavior of a hydrophilic drug [7].
In summary, the high efficiency of impregnation, the high drug loading, and the better progressive
release—without a burst stage—makes it an excellent choice in this application. In addition, it would
allow for treatment of other pathologies beyond PCa, such as locoregional applications in unresectable
cancers where intraperitoneal therapy may be a suitable delivery route. This approach has shown
better prognosis and a longer survival rate for small tumors in patients with ovarian cancer [58].
The stable and continuous release would circumvent the toxicity normally associated with transferring
approved intravenous protocols to an intraperitoneal bolus of the entire dose all-at-once [59], using, in
this case, a biodegradable polymer that is well tolerated in locoregional applications in humans and
is considered the polymer of choice for intraperitoneal treatments [60], as well as a drug that has an
inherent low toxicity [28]. It would also be a suitable approach for solid pancreatic tumors, which are
challenging to treat with chemotherapy because of their hypovascular and poorly perfused nature [61].
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4.3. Antitumor Effect of Curcumin Preparations in PC3, DU145, and 22rv1 Subcutaneous Xenografts
Curcumin has high anticancer effects in in vitro tumor models and a relatively low anti-tumor
effects in vivo. This could be due to its poor bioavailability, which restricts its application. In our
study, we demonstrate that PLGA polymer impregnation with curcumin represents a good strategy to
increase its effectiveness. We observed that impregnated curcumin shows higher anti-tumor effects
over the oral curcumin preparation, which results in a ~2-fold increase in effectiveness when compared
with MicroActive® curcumin administration. We observed that animals remained healthy, as indicated
by the relatively low body weight loss (Table 1). PLGA-impregnated curcumin preparation formed
a foreign body granuloma-type lesion, which tends to disappear with the time concomitantly with
the reabsorption of PLGA and release of curcumin. The more robust effectiveness was likely due to
the higher concentration of curcumin in the tumor tissue, which would intensify the local anti-tumor
effects as indicated by reduced Ki67-positivity and increased cell death. Apoptosis observed in several
reports using curcumin was also associated with an increased fibrotic reaction in the treated tumor, as
indicated by trichrome staining, as well as by reduced CD31 staining and vessel formation (not shown).
We observed that impregnated curcumin does not appear to affect the health of the animals, as shown
by the small body weight variation between groups (less than 10%, Table 1). We would conclude from
this that there are no adverse side effects from the use of this curcumin preparation with regard to the
doses released.
5. Conclusions
Curcumin is a natural anti-cancer compound that has been tested on a wide variety of human
cancer cell lines and animal carcinogenesis models. Although chemotherapy is a cornerstone in
the treatment of cancers in clinical practice, its efficacy is commonly restricted by an insufficient
concentration of the drug at the malignant tissue and undesired side effects. While curcumin is
regarded as an active anti-neoplastic agent, the major hurdle for its use as a chemotherapeutic agent
is its low bioavailability, which limits its application. Several approaches have been developed to
circumvent this problem without interfering with the anti-tumor effects of curcumin.
PLGA polymer impregnation with curcumin seems to be an effective strategy to increase its
effectiveness. The procedure for generating this type of polymer impregnated with curcumin is
relatively simple and the conditions are well established, which should allow reproducibility and high
impregnation yields to be achieved. This approach produces a slow release of curcumin release that
could be theoretically maintained at a high level in the tumor for up to 10 days, with little lost by
metabolism and intestinal uptake.
The distance between the site of injection of the tumor cells into the flanks and the subcutaneous
dorsal application of the impregnated curcumin showed a systemic effect. The brief temporary
adverse effects found around the dorsal pocket, suggest that the same compound could also be used in
loco-regional approaches. In intraperitoneal applications or in the treatment of solid tumors such as
pancreatic tumors, drug access is difficult due to its hypovascular and poorly perfused nature.
In summary, we report that curcumin-impregnated PLGA administered subcutaneously to
PCa xenografts shows a clear and robust anti-tumor effect, with the bioavailability and controlled
release of the curcumin likely responsible for an increase in anti-tumor responses compared with oral
administration. PLGA particles are, thus, a potential delivery system that may hold promise for in vivo
studies in other cancer types that might benefit from curcumin-related compounds.
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